The Beginner’s Guide to Psilocybin Mushrooms

[1] Passie, T., Seifert, J., Schneider, U. and Emrich, HM (2002). The pharmacology of psilocybin. Biology of Addiction, 7(4), 357–364. Extract of : https://maps.org/research-archive/w3pb/2002/2002_Passie_22704_1.pdf.

[2] Johnson, MW, Sewell, RA and Griffiths, RR (2012). Psilocybin causes, in a dose-dependent manner, delayed transient headaches in healthy volunteers. Drug and alcohol addiction, 123(1), 132–140. Extract of : https://cpdd.org/publications/drug-and-alcohol-dependence/.

[3] Studerus, E., Kometer, M., Hasler, F., & Vollenweider, FX (2011). Acute, subacute, and long-term subjective effects of psilocybin in healthy men: a pooled analysis of experimental studies. Journal of Psychopharmacology, 25(11), 1434–1452. Extract of : https://journals.sagepub.com/doi/full/10.1177/0269881110382466.

[4] van Amsterdam, J., Opperhuizen, A., & van den Brink, W. (2011). Harmful potential of using magic mushrooms: a review. Regulatory toxicology and pharmacology, 59(3), 423–429. Extract of : https://www.ovid.com/product-details.12163.html.

[5] Vollenweider, FX, & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 642–651. Extract of : https://www.nature.com/articles/nrn2884.

[6] Grob, CS, Danforth, AL, Chopra, GS, Hagerty, M., McKay, CR, Halberstadt, AL & Greer, GR (2011). Pilot study on the treatment of anxiety with psilocybin in patients with advanced cancer. General Psychiatry Archives, 68(1), 71–78. Extract of : https://jamanetwork.com/journals/jamapsychiatry/fullarticle/210962.

[7] Carhart-Harris et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. Extract of : https://www.thelancet.com/action/showPdf?pii=S2215-0366%2816%2930065-7.

[8] Moreno, FA, Wiegand, CB, Taitano, EK and Delgado, PL (2006). Safety, tolerability and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(11), 1735–1740. Extract of : https://maps.org/research-archive/w3pb/2006/2006_Moreno_22868_1.pdf.

[9] Bogenschutz, MP, Forcehimes, AA, Pommy, JA, Wilcox, CE, Barbosa, PCR and Strassman, RJ (2015). Psilocybin-assisted treatment of alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. Extract of : https://www.researchgate.net/publication/270909625_Psilocybin-assisted_treatment_for_alcohol_dependence_A_proof-of-concept_study.

[10] Johnson, MW, Garcia-Romeu, A., Cosimano, MP and Griffiths, RR (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology. Extract of : https://journals.sagepub.com/doi/10.1177/0269881114548296.

[11] Sewell, RA, Halpern, JH and Pope, HG (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12), 1920-1922. Extract of : http://www.en.psilosophie.info/pdf/response_of_cluster_headache_to_psilocybin_and_lsd_(psilocybin_and_lsd_(psilosophie.info).pdf.

[12] Schindler et al (2015). Hallucinogen indoleamines in cluster headaches: results from the Clusterbusters drug utilization survey. J Psychoactive drugs, 47(5), 372-381. Extract of : https://www.tandfonline.com/doi/abs/10.1080/02791072.2015.1107664?journalCode=ujpd20.

[13] Research on psilocybin and LSD as a treatment for cluster headaches. Extract of
https://maps.org/research-archive/html_bak/totestcsses.html

[14] Psilocybin for the treatment of cluster headaches. Extract of
https://clinicaltrials.gov/ct2/show/NCT02981173

[15] Carhart-Harris et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA, 109(6):2138-43. Extract of : https://www.pnas.org/content/pnas/109/6/2138.full.pdf.

[16] Carhart-Harris et al. (2017). Psilocybin for treatment-resistant depression: brain mechanisms measured by fMRI. Scientific reports, seven:13187. Extract of : https://www.nature.com/articles/s41598-017-13282-7.pdf.

[17] Leary, T., Litwin, GH and Metzner, R. (1963). Reactions to psilocybin administered in a supportive environment. The Journal of Nervous and Mental Illnesses, 137(6), 561–573. Extract of : https://journals.lww.com/jonmd/Citation/1963/12000/REACTIONS_TO_PSILOCYBJN_ADMINISTERED_IN_A.7.aspx.

[18] Alpert, R., Leary, T., & Metzner, R. (1971). The psychedelic experience. Extract of : https://amzn.to/3fXDXFI.

[19] Studerus, E., Gamma, A., & Vollenweider, FX (2010). Psychometric assessment of the Altered States of Consciousness (OAV) Rating Scale. PLOS ONE, 5(8), e12412. Extract of : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0012412&type=printable.

[20] Griffiths, RR, Richards, WA, Johnson, MW, McCann, UD & Jesse, R. (2008). Mystical-like experiences occasioned by psilocybin mediate the attribution of personal significance and spiritual significance 14 months later. Journal of Psychopharmacology. Extract of : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3050654/pdf/nihms252841.pdf.

[21] Carhart-Harris, RL, Erritzoe, D., Williams, T., Stone, JM, Reed, LJ, Colasanti, A., … others. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143. Extract of : https://www.pnas.org/content/pnas/109/6/2138.full.pdf.

[22] Restructuring of consciousness – the psychedelic state in the light of integrated information theory. Extract of https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464176/

[23] Griffiths et al. (2017). The mystical-like experience occasioned by psilocybin in combination with meditation and other spiritual practices produces lasting positive changes in psychological functioning and in measures of traits of prosocial attitudes and behaviors. J Psychopharma. Extract of : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772431/pdf/10.1177_0269881117731279.pdf.

[24] Denver Psilocybin Mushroom Decriminalization Initiative. Title and text of the ballot. Extract of https://static1.squarespace.com/static/5bb4f9c27046803ce123a760/t/5c6360158165f54e1f1b090a/1550016533926/DPMDI.pdf.

[25] PA. (2019, June 5). The latest: Oakland 2nd American city to legalize magic mushrooms. Extract of https://www.apnews.com/ff023dfbf4534eba8622f504d272ff00.

[26] Decriminalize Nature Oakland. Resolution. Extract of https://www.decriminalizenature.org/dno-resolution.

[27] Samorini, G. (2009). The oldest depictions of hallucinogenic mushrooms in the world. Extract of : https://pdfs.semanticscholar.org/249d/d61313bc743fee0a556d6a6252a1a541c1cb.pdf?_ga=2.183696166.1455736836.1593080084-259026952.1593080084.

[28] Passie, T., Seifert, J., Schneider, U. and Emrich, HM (2002). The pharmacology of psilocybin. Addiction Biology, seven(4), 357–364. Extract of : https://maps.org/research-archive/w3pb/2002/2002_Passie_22704_1.pdf.

[29] Teresi, D. (2007, June 3). Shroom: A Cultural History of the Magic Mushroom – Andy Letcher – Books – Exam. The New York Times.

[30] Psychotropic substances.

[31] Krebs, TS, & Johansen, P.-Ø. (2013). Over 30 million users of psychedelics in the United States. F1000Research. Extract of : https://pdfs.semanticscholar.org/6ee7/374715292bfe3a16cb61f820a4bdc92164cc.pdf?_ga=2.220896664.1455736836.1593080084-259026952.1593080084.

[32] Hallock, RM, Dean, A., Knecht, ZA, Spencer, J. & Taverna, EC (2013). A survey of hallucinogenic mushroom use, factors related to use, and perceptions of use among college students. Drug and alcohol addiction, 130(1), 245–248. Extract of : https://www.sciencedirect.com/science/article/abs/pii/S0376871612004516?via%3Dihub.

[33] Peden, NR, Macaulay, KEC, Bissett, AF, Crooks, J., & Pelosi, AJ (1981). Clinical toxicology of “magic mushroom” ingestion. Postgraduate Medical Journal, 57(671), 543–545. Extract of : https://pmj.bmj.com/content/postgradmedj/57/671/543.full.pdf.

[34] Passie, T., Seifert, J., Schneider, U. and Emrich, HM (2002). The pharmacology of psilocybin. Biology of Addiction, 7(4), 357–364. Extract of : https://maps.org/research-archive/w3pb/2002/2002_Passie_22704_1.pdf.

[35] van Amsterdam, J., Opperhuizen, A., & van den Brink, W. (2011). Harmful potential of using magic mushrooms: a review. Regulatory Toxicology and Pharmacology, 59(3), 423–429. Extract of : https://www.sciencedirect.com/science/article/abs/pii/S0273230011000080?via%3Dihub.

[36] Vollenweider, FX, Vollenweider-Scherpenhuyzen, MF, Bäbler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action. Neuroreport, 9(17), 3897–3902. Extract of : https://journals.lww.com/neuroreport/Abstract/1998/12010/Psilocybin_induces_schizophrenia_like_psychosis_in.24.aspx.

[37] L, S., H, G., & K, C. (2004). Poisoning resulting from the ingestion of magic mushrooms in Krakow. Przeglad Lekarski, 62(6), 394–396. Extract of : http://www.oit.cm.uj.edu.pl/documents/31784089/35444205/Magic_mushroom2005.pdf.

[38] Hendricks, PS, Thorne, CB, Clark, CB, Coombs, DW and Johnson, MW (2015). Consumption of classic psychedelics is associated with reduced psychological distress and suicidal tendencies in the adult population of the United States. Journal of Psychopharmacology, 29(3), 280–288. Extract of : https://journals.sagepub.com/doi/10.1177/0269881114565653.

[39] Nichols DE (2004) Hallucinogens. Pharmacology and therapeutics, 101, 131-181. Extract of : https://www.sciencedirect.com/science/article/abs/pii/S0163725803001657?via%3Dihub.

[40]Erowid Psilocybin Mushroom Vault: Drug Testing. Extract of : https://erowid.org/plants/mushrooms/mushrooms_testing.shtml.

Calvin W. Soper